File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Drug Repurposing for the Treatment of COVID‐19: A Knowledge Graph Approach

TitleDrug Repurposing for the Treatment of COVID‐19: A Knowledge Graph Approach
Authors
Issue Date2021
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2366-3987
Citation
Advanced Therapeutics, 2021, v. 4 n. 7, p. article no. 2100055 How to Cite?
AbstractIdentifying effective drug treatments for COVID-19 is essential to reduce morbidity and mortality. Although a number of existing drugs have been proposed as potential COVID-19 treatments, effective data platforms and algorithms to prioritize drug candidates for evaluation and application of knowledge graph for drug repurposing have not been adequately explored. A COVID-19 knowledge graph by integrating 14 public bioinformatic databases containing information on drugs, genes, proteins, viruses, diseases, symptoms and their linkages is developed. An algorithm is developed to extract hidden linkages connecting drugs and COVID-19 from the knowledge graph, to generate and rank proposed drug candidates for repurposing as treatments for COVID-19 by integrating three scores for each drug: motif scores, knowledge graph PageRank scores, and knowledge graph embedding scores. The knowledge graph contains over 48 000 nodes and 13 37 000 edges, including 13 563 molecules in the DrugBank database. From the 5624 molecules identified by the motif-discovery algorithms, ranking results show that 112 drug molecules had the top 2% scores, of which 50 existing drugs with other indications approved by health administrations reported. The proposed drug candidates serve to generate hypotheses for future evaluation in clinical trials and observational studies.
DescriptionBronze open access
Persistent Identifierhttp://hdl.handle.net/10722/301234
ISSN
2023 Impact Factor: 3.7
2023 SCImago Journal Rankings: 1.063
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYan, V-
dc.contributor.authorLi, X-
dc.contributor.authorYE, X-
dc.contributor.authorOu, M-
dc.contributor.authorLuo, R-
dc.contributor.authorZhang, Q-
dc.contributor.authorTang, B-
dc.contributor.authorCowling, BJ-
dc.contributor.authorHung, I-
dc.contributor.authorSiu, CW-
dc.contributor.authorWong, ICK-
dc.contributor.authorCheng, RCK-
dc.contributor.authorChan, EW-
dc.date.accessioned2021-07-27T08:08:06Z-
dc.date.available2021-07-27T08:08:06Z-
dc.date.issued2021-
dc.identifier.citationAdvanced Therapeutics, 2021, v. 4 n. 7, p. article no. 2100055-
dc.identifier.issn2366-3987-
dc.identifier.urihttp://hdl.handle.net/10722/301234-
dc.descriptionBronze open access-
dc.description.abstractIdentifying effective drug treatments for COVID-19 is essential to reduce morbidity and mortality. Although a number of existing drugs have been proposed as potential COVID-19 treatments, effective data platforms and algorithms to prioritize drug candidates for evaluation and application of knowledge graph for drug repurposing have not been adequately explored. A COVID-19 knowledge graph by integrating 14 public bioinformatic databases containing information on drugs, genes, proteins, viruses, diseases, symptoms and their linkages is developed. An algorithm is developed to extract hidden linkages connecting drugs and COVID-19 from the knowledge graph, to generate and rank proposed drug candidates for repurposing as treatments for COVID-19 by integrating three scores for each drug: motif scores, knowledge graph PageRank scores, and knowledge graph embedding scores. The knowledge graph contains over 48 000 nodes and 13 37 000 edges, including 13 563 molecules in the DrugBank database. From the 5624 molecules identified by the motif-discovery algorithms, ranking results show that 112 drug molecules had the top 2% scores, of which 50 existing drugs with other indications approved by health administrations reported. The proposed drug candidates serve to generate hypotheses for future evaluation in clinical trials and observational studies.-
dc.languageeng-
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2366-3987-
dc.relation.ispartofAdvanced Therapeutics-
dc.rightsSubmitted (preprint) Version This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Accepted (peer-reviewed) Version This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.titleDrug Repurposing for the Treatment of COVID‐19: A Knowledge Graph Approach-
dc.typeArticle-
dc.identifier.emailYan, V: kcyan96@hku.hk-
dc.identifier.emailLuo, R: rbluo@cs.hku.hk-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.emailHung, I: ivanhung@hkucc.hku.hk-
dc.identifier.emailSiu, CW: cwdsiu@hkucc.hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailCheng, RCK: ckcheng@cs.hku.hk-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.authorityLuo, R=rp02360-
dc.identifier.authorityCowling, BJ=rp01326-
dc.identifier.authorityHung, I=rp00508-
dc.identifier.authoritySiu, CW=rp00534-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityCheng, RCK=rp00074-
dc.identifier.authorityChan, EW=rp01587-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/adtp.202100055-
dc.identifier.pmid34179346-
dc.identifier.pmcidPMC8212091-
dc.identifier.scopuseid_2-s2.0-85106031582-
dc.identifier.hkuros323785-
dc.identifier.volume4-
dc.identifier.issue7-
dc.identifier.spagearticle no. 2100055-
dc.identifier.epagearticle no. 2100055-
dc.identifier.isiWOS:000652290000001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats